China’s Government Might Phase Out Ad Hoc Price Controls On Drugs
This article was originally published in PharmAsia News
Executive Summary
BEIJING - China's National Development and Reform Commission is mulling proposals to phase out its fluctuating and sometimes opaque price control policies on pharmaceuticals in favor of a more rational and open system, according to an analyst briefed on the issue
You may also be interested in...
China Eager To Establish Pharmacovigilance System – SFDA Officials
SHANGHAI - In an effort to ensure drug safety, China will establish a pharmacovigilance system and will continue to improve its adverse drug reaction reports system, said Yan Ming, director of the drug re-evaluation division under China's State FDA drug safety and inspection department, during an international conference on post-market drug safety Oct. 29 in Shanghai
China Eager To Establish Pharmacovigilance System – SFDA Officials
SHANGHAI - In an effort to ensure drug safety, China will establish a pharmacovigilance system and will continue to improve its adverse drug reaction reports system, said Yan Ming, director of the drug re-evaluation division under China's State FDA drug safety and inspection department, during an international conference on post-market drug safety Oct. 29 in Shanghai
Global Pharma Giants Concered About China’s New Anti-Monopoly Law
BEIJING - Leading executives at multinational firms operating in China, including some pharmaceutical giants, are concerned that the country's new anti-monopoly law could be used to counter strong market positions or to forced licensing of innovative products to competitors